3.3 Analysis of maternal-fetal paired single nucleotide polymorphisms
In order to figure out whether mother with Val66Met mutation will effect the SNP of fetus, we performed mother-fetal pairing to explore whether the site was transferred from mother to fetus. Tthe results of SNP analysis in paired pregnant women were basically consistent with the results obtained from large samples. The difference between the BDNF gene Val66Met locus allele case group and the control group was statistically significant (χ2=9.054, P=0.003, OR=0.630, 95%CI=0.466-1.852). However, there was no significant difference in genotype (χ2 = 0.634, P = 0.728) and additive genes (χ2 = 0.477, P = 0.49, OR = 0.846, 95% CI = 0.525-1.362)(Table 3). Besides, Val66Met loci in BDNF gene of newborns in paired samples showed no significant difference in genotype distribution (χ2 = 1.883, P = 0.390), alleles (χ2 = 1.791, P = 0.181, OR = 1.208, 95% CI = 0.916-1.592) and additive genes ( χ2 = 1.407, P = 0.235, OR = 1.369, 95% CI = 0.814-2.304) between the two groups(Table 4).
We wondering whether Val166Met may have a potential impact on the occurrence of new born poor prognosis associated with PE. So, we performed pairing classification for maternal-fetal BDNF Val66Met locus phenotype. However, the results showed that there was no significant difference between the case group and the control group in the maternal-fetal transmission. (χ2 = 4.896, P = 0.086). See Table 5.